ASTHMA IS COMPLICATED. WE BELIEVE WE CAN MAKE IT SIMPLER. Airway inflammation is the major underlying cause of asthma. FeNO is a biomarker of Type 2 inflammation and FeNO testing can help achieve better management and outcomes in asthma patients. Circassia is the world leader in FeNO testing. Our NIOX® products are used by specialists throughout the US and around the world. NIOX®, THE GOLD STANDARD IN FENO TESTING With over 40 million FeNO tests performed worldwide, NIOX VERO® helps healthcare professionals to accurately measure Type 2 airway inflammation. NIOX® technology eliminates the impact of environmental nitric oxide and ensures you get an accurate FeNO result each time, every time. NIOX VERO® can help with: - Diagnosis: Identifying Type 2 inflammation and assisting in asthma diagnosis - Treatment: Identifying patients likely to respond to ICS and optimising ICS dosage - Compliance: Uncovering non-adherence to ICS treatment - Quality of life: Predicting exacerbations and reducing exacerbation rate by up to 50% (add ‘in patients at risk’ for the US only) - Severe asthma: Identifying appropriate patients for some biologics and monitoring response to biologics Find out more about NIOX VERO® here: https://niox.com